Goldman Sachs initiated coverage of Corvus Pharmaceuticals (CRVS) with a Buy rating and $40 price target The shares trade at an attractive entry point given the company’s “leading emerging” oral option in the “large” post-Dupixent atopic dermatitis market, the analyst tells investors in a research note. The firm believes Corvus’ valuation does not reflect the potential of its “differentiated, emerging” oral option for atopic dermatitis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline
- Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million
- Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer
- Corvus Pharmaceuticals files automatic mixed securities shelf
- Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile